EP3582781A4 - A method of treatment - Google Patents

A method of treatment Download PDF

Info

Publication number
EP3582781A4
EP3582781A4 EP18754206.3A EP18754206A EP3582781A4 EP 3582781 A4 EP3582781 A4 EP 3582781A4 EP 18754206 A EP18754206 A EP 18754206A EP 3582781 A4 EP3582781 A4 EP 3582781A4
Authority
EP
European Patent Office
Prior art keywords
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP18754206.3A
Other languages
German (de)
French (fr)
Other versions
EP3582781A1 (en
Inventor
Simon R BAILEY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Melbourne
Original Assignee
University of Melbourne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017900491A external-priority patent/AU2017900491A0/en
Application filed by University of Melbourne filed Critical University of Melbourne
Publication of EP3582781A1 publication Critical patent/EP3582781A1/en
Publication of EP3582781A4 publication Critical patent/EP3582781A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
EP18754206.3A 2017-02-15 2018-02-15 A method of treatment Pending EP3582781A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2017900491A AU2017900491A0 (en) 2017-02-15 A method of treatment
PCT/AU2018/050120 WO2018148797A1 (en) 2017-02-15 2018-02-15 A method of treatment

Publications (2)

Publication Number Publication Date
EP3582781A1 EP3582781A1 (en) 2019-12-25
EP3582781A4 true EP3582781A4 (en) 2020-12-09

Family

ID=63169104

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18754206.3A Pending EP3582781A4 (en) 2017-02-15 2018-02-15 A method of treatment

Country Status (4)

Country Link
US (1) US11123349B2 (en)
EP (1) EP3582781A4 (en)
AU (1) AU2018221891B2 (en)
WO (1) WO2018148797A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3128468A1 (en) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
WO2021076961A1 (en) * 2019-10-16 2021-04-22 University Of South Florida Compositions and methods of treatment for inhibiting capillary tube regression

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6525046B1 (en) * 2000-01-18 2003-02-25 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as antiinflammatory agents
WO2005100338A1 (en) * 2004-04-13 2005-10-27 Astex Therapeutics Limited 5-morpholinylmethylthiophenyl pharmaceutial compounds as p38 map kinase modulators

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA73492C2 (en) 1999-01-19 2005-08-15 Aromatic heterocyclic compounds as antiinflammatory agents
CA2454913A1 (en) 2001-08-20 2003-02-27 Boehringer Ingelheim Pharmaceuticals, Inc. Parenteral formulations of 1-(5-tert-butyl-2-p-tolyl-2h-pryrazol-3-yl)-3-¬4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl|-urea and a cyclodextrin
CA2550064A1 (en) * 2003-12-18 2005-07-07 Pfizer Products Inc. Methods of treating acute inflammation in animals with p38 map kinase inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6525046B1 (en) * 2000-01-18 2003-02-25 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as antiinflammatory agents
WO2005100338A1 (en) * 2004-04-13 2005-10-27 Astex Therapeutics Limited 5-morpholinylmethylthiophenyl pharmaceutial compounds as p38 map kinase modulators

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JENNIFER BAUQUIER ET AL: "inhibitor doramapimod on the systemic inflammatory response to intravenous lipopolysaccharide in horses", JOURNAL OF VETERINARY INTERNAL MEDICINE, vol. 34, no. 5, 23 July 2020 (2020-07-23), US, pages 2109 - 2116, XP055743816, ISSN: 0891-6640, DOI: 10.1111/jvim.15847 *
NEUDER L E ET AL: "Role of p38 MAPK in LPS induced pro-inflammatory cytokine and chemokine gene expression in equine leukocytes", VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, ELSEVIER BV, AMSTERDAM, NL, vol. 129, no. 3-4, 15 June 2009 (2009-06-15), pages 192 - 199, XP026018783, ISSN: 0165-2427, [retrieved on 20081107], DOI: 10.1016/J.VETIMM.2008.11.006 *
See also references of WO2018148797A1 *

Also Published As

Publication number Publication date
US11123349B2 (en) 2021-09-21
AU2018221891A1 (en) 2019-09-05
AU2018221891B2 (en) 2023-05-25
EP3582781A1 (en) 2019-12-25
US20200061074A1 (en) 2020-02-27
WO2018148797A1 (en) 2018-08-23

Similar Documents

Publication Publication Date Title
EP3426250A4 (en) Methods of treatment
EP3307286A4 (en) A method of treatment
EP3402513A4 (en) Method of treating influenza a
EP3684342A4 (en) Method of treatment
EP3209319A4 (en) A method of treatment
EP3645030A4 (en) A method of treatment
EP3582781A4 (en) A method of treatment
EP3681536A4 (en) Treatment method
EP3253388A4 (en) A method of treatment and compounds for use therein
EP3493821A4 (en) A method of treatment
EP3490547A4 (en) Method of treatment
EP3574003A4 (en) A method of treatment
EP3597225A4 (en) Treatment method
EP3727376A4 (en) Methods of treatment of hypertrigl yceridemia
AU2017904807A0 (en) A method of treatment
AU2017903933A0 (en) A method of treatment
AU2017903041A0 (en) A Method of Treatment
AU2017902742A0 (en) A method of treatment
AU2017902545A0 (en) A method of treatment
AU2017900491A0 (en) A method of treatment
AU2017900251A0 (en) A method of treatment
AU2017900207A0 (en) A Method of Treatment
AU2018904196A0 (en) A Method of Treatment
AU2016903060A0 (en) A method of treatment
AU2017904855A0 (en) Method of treatment

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190813

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20201106

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 29/00 20060101ALI20201102BHEP

Ipc: A61P 43/00 20060101ALI20201102BHEP

Ipc: A61K 31/5377 20060101AFI20201102BHEP

Ipc: A61K 31/4015 20060101ALI20201102BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20230728